We hypothesize that targeted delivery of Curcumin to antigen presenting cells in the immune system can suppress tumor growth for a variety of cancers. This study will examine tumor responses to Curcumin in a colon cancer mouse model when given alone or in combination with an FDA-approved immune Checkpoint Inhibitor. Positive results will lead to Fast-Track FDA applications for human and companion pet animal cancer trials.